Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1312.73% is 66% below its 1-year average of -788.96%, near the low end of its 1-year range (-1684.71%–-429.12%).
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -584.83%.
EBITDA MARGIN
-1312.73%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
NRx Pharmaceuticals, Inc.
Market Cap
$124.91M
EBITDA Margin
-1312.73%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$122.89M
EBITDA Margin
-1691.15%
TTM Avg
-1668.02%
3Y Avg
-8474.77%
5Y Avg
-5696.48%
Market Cap
$128.40M
EBITDA Margin
-27378.57%
TTM Avg
-16324.37%
3Y Avg
-14117.74%
5Y Avg
-9505.20%
Market Cap
$118.83M
EBITDA Margin
-475.96%
TTM Avg
-475.96%
3Y Avg
-272.89%
5Y Avg
-272.89%
Market Cap
$131.16M
EBITDA Margin
4.63%
TTM Avg
-2.31%
3Y Avg
-16.32%
5Y Avg
-24.77%
Market Cap
$117.29M
EBITDA Margin
-254.71%
TTM Avg
-369.64%
3Y Avg
-290.17%
5Y Avg
-290.17%
Market Cap
$117.03M
EBITDA Margin
-1187.82%
TTM Avg
-1407.84%
3Y Avg
-970.99%
5Y Avg
-809.42%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NRx Pharmaceuticals, Inc. (NRXP) | $124.91M | -1312.73% | N/A | N/A | N/A |
| enGene Holdings Inc. (ENGN)vs › | $123.03M | N/A | N/A | N/A | N/A |
| Cibus, Inc. (CBUS)vs › | $122.89M | -1691.15% | -1668.02% | -8474.77% | -5696.48% |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.63M | N/A | N/A | N/A | N/A |
| Entera Bio Ltd. (ENTX)vs › | $128.40M | -27378.57% | -16324.37% | -14117.74% | -9505.20% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | -475.96% | -475.96% | -272.89% | -272.89% |
| Health Catalyst, Inc. (HCAT)vs › | $131.16M | 4.63% | -2.31% | -16.32% | -24.77% |
| Coya Therapeutics, Inc. (COYA)vs › | $117.29M | -254.71% | -369.64% | -290.17% | -290.17% |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.03M | -1187.82% | -1407.84% | -970.99% | -809.42% |
| Genelux Corporation (GNLX)vs › | $116.59M | -408000.00% | -396456.25% | -201636.71% | -201636.71% |
Gross Margin
58.8%
EBITDA Margin
-1312.7%
Operating Margin
-1324.4%
Net Margin
-691.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -584.83% |
| 2026-03-31 | -429.12% |
| 2025-12-31 | -457.17% |
| 2025-09-30 | -1684.71% |
